About Us

OUR MISSION IS TO LEAD AN EVOLUTION IN TRANSLATIONAL ONCOLOGY VIA NOVEL INSIGHTS INTO HUMAN TUMOR BIOLOGY GENERATED BY THE CIVO PLATFORM

About Presage

Presage’s patented CIVO® (Comparative In Vivo Oncology) technology delivers microdoses of multiple drugs to different regions of a tumor, while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in a naturally occurring tumor has the potential to provide a more detailed understanding of tumor biology. This method directly captures a patients own immune system, tumor microenvironment, and genetic background. It is Presage’s mission to improve the way that new drugs are developed and targeted, with the goal of ultimately providing more effective treatments to patients with cancer.

Presage collaborates with other innovators who want to be at the forefront of oncology drug development. We work together to understand the myriad complexities of the tumor microenvironment and with our CIVO platform, explore the most important model of cancer – the human patient.

Preclinical CIVO Offerings Available

CIVO highlights immune effects in syngeneic models

Experienced preclinical
Team
Excellent for pilot studies
Prior to Clinical CIVO
In-house
Vivarium & IACUC
Amenable to ALL
Drug modalities
Full tumor model, histology
And image analysis support
Small
Molecule

Preclinical CIVO Offerings Available

CIVO highlights immune effects in syngeneic models

Cancer Drug Development Needs More Predictive Platforms For Testing Candidate Agents

One important bottleneck in oncology drug development is the inability of preclinical models to accurately model the tumor microenvironment in human patients.

CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY

Nine US Patents Issued

Presage's Partners

A pioneering solution, turnkey operation, revenue-generating partnerships2016 - 2021

CIVO IS A PIONEERING SOLUTION TO A HOST OF FUNDAMENTAL
PROBLEMS INHERENT IN ONCOLOGY DRUG DISCOVERY

Nine Patents Issued
in the United States

Nine issued US patents
“A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.”